If the page does not redirect, click here
Studies show effectiveness of combo treatment for HCV patients with, without cirrhosis
Patients with chronic hepatitis C virus genotype 1 infection and with or without cirrhosis achieved high rates of sustained virologic response after 12 weeks of treatment with a combination of the direct-acting-antiviral drugs daclatasvir, asunaprevir, and beclabuvir, researchers report.